Calliditas Therapeutics US Inc. |
81749000401 |
TARPEYO™ (budesonide) delayed release capsules |
2022-01-27 |
14160.0000 |
None |
1 |
4000 |
None |
1 |
None |
None |
None |
None |
Estimated Number of Patients: There is no ICD-10 code for IgA Nephropathy and no IgA Nephropathy patient registry in the state. The estimated IgAN incidence in the US based on native biopsy is 4000 - 4500 IgAN patients. |
None |
Camber Pharmaceuticals, Inc. |
31722057960 |
Maraviroc 150mg 60ct |
2022-02-07 |
1410.8200 |
None |
1 |
1200000 |
None |
None |
None |
None |
None |
None |
None |
None |
Camber Pharmaceuticals, Inc. |
31722058060 |
Maraviroc 300mg 60ct |
2022-02-07 |
1410.8200 |
None |
1 |
1200000 |
None |
None |
None |
None |
None |
None |
None |
None |
Camber Pharmaceuticals, Inc. |
31722087227 |
Pirfenidone 267mg 270ct |
2022-10-01 |
1800.0000 |
None |
1 |
100000 |
None |
None |
None |
None |
None |
None |
None |
None |
Camber Pharmaceuticals, Inc. |
31722087390 |
Pirfenidone 801mg 90ct |
2022-10-01 |
1800.0000 |
None |
1 |
100000 |
None |
None |
None |
None |
None |
None |
None |
None |
Camber Pharmaceuticals, Inc. |
31722088930 |
Fingolimod 0.5mg 30ct |
2022-10-17 |
3681.7300 |
None |
1 |
1000000 |
None |
None |
None |
None |
None |
None |
None |
None |
Celltrion USA, Inc. |
72606057301 |
Abiraterone Acetate 500mg |
2022-01-21 |
4219.5400 |
This product is a generic equivalent of an existing innovator product. Celltrion USA, Inc. does not engage in direct-to-consumer marketing and paid advertising to consumers, physicians, or other healthcare professionals for its generic products. |
None |
4500 |
None |
None |
None |
None |
None |
None |
None |
None |
Cerona Therapeutics, Inc. |
81643927001 |
Floxuridine; for injection; sterile,nonpyrogenic, lyophilized powder for reconstitution; Each vial (packaged individually) contains 500 mg of floxuridine to be reconstituted with 5 mL of sterile water for injection |
2022-06-27 |
3350.0000 |
None |
1 |
1000 |
None |
None |
None |
None |
None |
None |
None |
None |
Chiesi USA |
10122050201 |
Revcovi® (elapegademase-IvIr 1.6mg/ml) Injection |
2022-04-18 |
11245.5900 |
None |
1 |
47 |
None |
1 |
2020-11-24 |
None |
1 |
Private company deal. Price not released. |
New NDC reflecting manufacturer's labeler code. |
None |
Cipla USA, Inc. |
69097087067 |
Lanreotide Injection 120mg/0.5ml Syringe 1ct |
2022-01-31 |
8892.6600 |
None |
1 |
175000 |
None |
None |
None |
None |
None |
None |
Product was not acquired |
None |
Cipla USA, Inc. |
69097093698 |
Lanthanum Carbonate Chew Tabs 1000mg 90's |
2022-02-25 |
971.4800 |
None |
1 |
558060 |
None |
1 |
None |
None |
None |
None |
Pricing for this product was submitted to data compendia on 2/2/2022, however the product was not commercially available until 2/25/2022. This product was not acquired. |
None |
Cipla USA, Inc. |
69097093498 |
Lanthanum Carbonate Chew Tabs 500 mg 90's |
2022-02-25 |
971.4800 |
None |
1 |
558060 |
None |
1 |
None |
None |
None |
None |
Pricing for this product was submitted to data compendia on 2/2/2022, however the product was not commercially available until 2/25/2022. This product was not acquired. |
None |
Cipla USA, Inc. |
69097093598 |
Lanthanum Carbonate Chew Tabs 750mg 90's |
2022-02-25 |
971.4800 |
None |
1 |
558060 |
None |
1 |
None |
None |
None |
None |
Pricing for this product was submitted to data compendia on 2/2/2022, however the product was not commercially available until 2/25/2022. This product was not acquired. |
None |
Cipla USA, Inc. |
69097098793 |
Pirfenidone Tabs 267mg 270ct |
2022-08-16 |
1800.0000 |
None |
1 |
100000 |
1 |
None |
2022-05-11 |
None |
1 |
Drug is licensed from another manufacturer, acquisition price represents licensing cost |
None |
None |
Cipla USA, Inc. |
69097098805 |
Pirfenidone Tabs 801mg 90ct |
2022-08-16 |
1800.0000 |
None |
1 |
100000 |
1 |
None |
2022-05-11 |
None |
1 |
Drug is licensed from another manufacturer, acquisition price represents licensing cost |
None |
None |
Cipla USA, Inc. |
69097038273 |
Lenalidomide Capsules 10mg 28 count |
2022-09-08 |
20157.3600 |
None |
1 |
34000 |
1 |
None |
None |
None |
None |
None |
None |
None |
Cipla USA, Inc. |
69097038381 |
Lenalidomide Capsules 15 mg 21 count |
2022-09-08 |
15118.0400 |
None |
1 |
34000 |
1 |
None |
None |
None |
None |
None |
None |
None |
Cipla USA, Inc. |
69097038581 |
Lenalidomide Capsules 25mg 21 count |
2022-09-08 |
15118.0400 |
None |
1 |
34000 |
1 |
None |
None |
None |
None |
None |
None |
None |
Cipla USA, Inc. |
69097038173 |
Lenalidomide Capsules 5mg 28’s |
2022-09-08 |
20157.3600 |
None |
1 |
34000 |
1 |
None |
None |
None |
None |
None |
None |
None |
Cipla USA, Inc. |
69097090950 |
Leuprolide acetate suspension 22.5mg/2ml syringe |
2022-11-22 |
1355.0700 |
None |
1 |
270000 |
None |
None |
None |
None |
None |
None |
drug not acquired |
None |
CMP Pharma |
46287004515 |
Tadalafil oral suspension, 20mg.5 mL, 150 mL bottle |
2022-10-12 |
1895.0000 |
None |
1 |
1000 |
None |
None |
None |
None |
None |
None |
None |
None |
Coherus BioSciences, Inc. |
70114044001 |
Each CIMERLI 0.3 mg carton contains a single-dose, 2-mL glass vial with a WHITE CAP designed to deliver 0.05 mL of 6 mg/mL ranibizumab-eqrn solution |
2022-10-03 |
816.0000 |
None |
1 |
1621598 |
None |
None |
None |
None |
None |
None |
None |
None |
Coherus BioSciences, Inc. |
70114044101 |
Each CIMERLI 0.5 mg carton contains a single-dose, 2-mL glass vial with a BLUE CAP designed to deliver 0.05 mL of 10 mg/mL ranibizumab-eqrn solution. |
2022-10-03 |
1360.0000 |
None |
1 |
1621598 |
None |
None |
None |
None |
None |
None |
None |
None |
CTI BioPharma Corp. |
72482010012 |
VONJO 100 mg capsule, 120 capsules |
2022-03-10 |
19500.0000 |
VONJO will be promoted by our commercial field team to healthcare professionals to educate them on our product. We will use various means of promotion including in-office visits, virtual meetings, ad campaigns, and digital marketing. Pricing was established by CTI BioPharma Corp. after conducting extensive market research and analysis, which included the research and development investment made, forecasted operational costs, and the overall competitive landscape to reach our determination of launch WAC price. Our launch WAC price is intended to reflect the drug’s specific value to patients within our indicated population and the healthcare providers who treat them. |
None |
7000 |
None |
1 |
None |
None |
None |
None |
None |
None |